Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
|
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 50 条
  • [41] Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Dash, Atreya
    Galsky, Matthew D.
    Vickers, Andrew J.
    Serio, Angel M.
    Koppie, Theresa M.
    Dalbagni, Guido
    Bochner, Bernard H.
    CANCER, 2006, 107 (03) : 506 - 513
  • [42] Chemotherapy in perioperative setting for infiltrative bladder cancer
    Houede, N.
    Beuzeboc, P.
    Culine, S.
    Soulie, M.
    Pfister, C.
    PROGRES EN UROLOGIE, 2012, 22 (03): : 139 - 145
  • [43] Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
    A V Khrunin
    A Moisseev
    V Gorbunova
    S Limborska
    The Pharmacogenomics Journal, 2010, 10 : 54 - 61
  • [44] Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
    Dulz, Simon
    Asselborn, Niels H.
    Dieckmann, Klaus-Peter
    Matthies, Cord
    Wagner, Walter
    Weidmann, Jens
    Seidel, Christoph
    Oing, Christoph
    Berger, Lars A.
    Alsdorf, Winfried
    Mankichian, Blanche
    Meyer, Christian
    Vetterlein, Malte W.
    Gild, Philipp
    Ludwig, Tim A.
    Soave, Armin
    Schriefer, Philipp
    Becker, Andreas
    Ahyai, Sascha A.
    Oechsle, Karin
    Bokemeyer, Carsten
    Wagenfeld, Lars
    Fisch, Margit
    Hartmann, Michael
    Chun, Felix K-H.
    Kluth, Luis A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1319 - 1325
  • [45] Why is perioperative chemotherapy for bladder cancer underutilized?
    Patafio, Francis M.
    Mackillop, William J.
    Feldman-Stewart, Deb
    Siemens, David Robert
    Booth, Christopher M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (04) : 391 - 395
  • [46] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
    Yafi, Faysal A.
    Kassouf, Wassim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
  • [47] CISPLATIN-BASED CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER - A REVIEW OF 36 CASES
    TAKESHIMA, N
    SHIMIZU, Y
    UMEZAWA, S
    HASUMI, K
    MASUBUCHI, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 2 (02) : 179 - 184
  • [48] sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients
    Ulukaya, Engin
    Acilan, Ceyda
    Yilmaz, Meryem
    Yilmaztepe-Oral, Arzu
    Ari, Ferda
    Zik, Berrin
    Ursavas, Ahmet
    Tokullugil, Asuman H.
    CELL BIOCHEMISTRY AND FUNCTION, 2010, 28 (07) : 565 - 570
  • [49] Pharmacogenomics of cisplatin-based chemotherapy in ovarian-cancer patients from Yakutia
    Khokhrin, D. V.
    Khrunin, A. V.
    Ivanova, F. G.
    Moisseev, A. A.
    Gorbunova, V. A.
    Limborska, S. A.
    MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY, 2013, 28 (04) : 137 - 140
  • [50] Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
    Simon Dulz
    Niels H. Asselborn
    Klaus-Peter Dieckmann
    Cord Matthies
    Walter Wagner
    Jens Weidmann
    Christoph Seidel
    Christoph Oing
    Lars A. Berger
    Winfried Alsdorf
    Blanche Mankichian
    Christian Meyer
    Malte W. Vetterlein
    Philipp Gild
    Tim A. Ludwig
    Armin Soave
    Philipp Schriefer
    Andreas Becker
    Sascha A. Ahyai
    Karin Oechsle
    Carsten Bokemeyer
    Lars Wagenfeld
    Margit Fisch
    Michael Hartmann
    Felix K-H. Chun
    Luis A. Kluth
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1319 - 1325
12345